These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 14736235)
1. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. Kenda BM; Matagne AC; Talaga PE; Pasau PM; Differding E; Lallemand BI; Frycia AM; Moureau FG; Klitgaard HV; Gillard MR; Fuks B; Michel P J Med Chem; 2004 Jan; 47(3):530-49. PubMed ID: 14736235 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. Leclercq K; Matagne A; Provins L; Klitgaard H; Kaminski RM J Pharmacol Exp Ther; 2020 Jan; 372(1):11-20. PubMed ID: 31619464 [TBL] [Abstract][Full Text] [Related]
3. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360 [TBL] [Abstract][Full Text] [Related]
4. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Noyer M; Gillard M; Matagne A; Hénichart JP; Wülfert E Eur J Pharmacol; 1995 Nov; 286(2):137-46. PubMed ID: 8605950 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives. Kamiński K; Rapacz A; Łuszczki JJ; Latacz G; Obniska J; Kieć-Kononowicz K; Filipek B Bioorg Med Chem; 2015 May; 23(10):2548-61. PubMed ID: 25868743 [TBL] [Abstract][Full Text] [Related]
6. Influence of levetiracetam on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice. Donato Di Paola E; Gareri P; Davoli A; Gratteri S; Scicchitano F; Naccari C; De Sarro G Epilepsy Res; 2007 Jul; 75(2-3):112-21. PubMed ID: 17553669 [TBL] [Abstract][Full Text] [Related]
7. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401 [TBL] [Abstract][Full Text] [Related]
8. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Gillard M; Fuks B; Michel P; Vertongen P; Massingham R; Chatelain P Eur J Pharmacol; 2003 Sep; 478(1):1-9. PubMed ID: 14555178 [TBL] [Abstract][Full Text] [Related]
9. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Gower AJ; Noyer M; Verloes R; Gobert J; Wülfert E Eur J Pharmacol; 1992 Nov; 222(2-3):193-203. PubMed ID: 1451732 [TBL] [Abstract][Full Text] [Related]
10. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Matagne A; Margineanu DG; Potschka H; Löscher W; Michel P; Kenda B; Klitgaard H Eur J Pharmacol; 2009 Jul; 614(1-3):30-7. PubMed ID: 19383493 [TBL] [Abstract][Full Text] [Related]
11. Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord. Lambeng N; Gillard M; Vertongen P; Fuks B; Chatelain P Eur J Pharmacol; 2005 Sep; 520(1-3):70-6. PubMed ID: 16125696 [TBL] [Abstract][Full Text] [Related]
12. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Gillard M; Fuks B; Leclercq K; Matagne A Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627 [TBL] [Abstract][Full Text] [Related]
13. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Klitgaard H Epilepsia; 2001; 42 Suppl 4():13-8. PubMed ID: 11564119 [TBL] [Abstract][Full Text] [Related]
14. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Fuks B; Gillard M; Michel P; Lynch B; Vertongen P; Leprince P; Klitgaard H; Chatelain P Eur J Pharmacol; 2003 Sep; 478(1):11-9. PubMed ID: 14555179 [TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Nicolas JM; Collart P; Gerin B; Mather G; Trager W; Levy R; Roba J Drug Metab Dispos; 1999 Feb; 27(2):250-4. PubMed ID: 9929511 [TBL] [Abstract][Full Text] [Related]
16. Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats. Kitano Y; Komiyama C; Makino M; Takasuna K; Takazawa A; Sakurada S Epilepsia; 2005 Jun; 46(6):811-8. PubMed ID: 15946322 [TBL] [Abstract][Full Text] [Related]
17. Brivaracetam: a rational drug discovery success story. Rogawski MA Br J Pharmacol; 2008 Aug; 154(8):1555-7. PubMed ID: 18552880 [TBL] [Abstract][Full Text] [Related]
18. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Genton P; Van Vleymen B Epileptic Disord; 2000 Jun; 2(2):99-105. PubMed ID: 10954241 [TBL] [Abstract][Full Text] [Related]
19. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Löscher W; Richter A Eur J Pharmacol; 2000 Mar; 391(3):251-4. PubMed ID: 10729365 [TBL] [Abstract][Full Text] [Related]
20. Effects of Nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats. Kitano Y; Komiyama C; Makino M; Kasai Y; Takasuna K; Kinoshita M; Yamazaki O; Takazawa A; Yamauchi T; Sakurada S Epilepsia; 2005 Oct; 46(10):1561-8. PubMed ID: 16190926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]